RxDoctor Payments Data

Setu Trivedi, DO

Interventional Cardiology · Elmhurst, ILNPI 1295053106

Payments from drug & device makers

$4,594in general payments, 2019–2025

Across 139 payments — averaging $33.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Novartis$493
  • Boehringer Ingelheim$273
  • Abiomed$256
  • Abbott$201
  • Inari Medical, Inc.$196
  • plus $2K from 27 others

What the payments were for

  • Travel & lodging$1,02522%
  • Food & beverage$3,56978%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,594 in reported general payments places this provider in the 30th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$281,633
Medicare patients
965
Services billed
3,296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban47$48,555
XareltoRivaroxaban34$37,269
BrilintaTicagrelor33$29,651
JardianceEmpagliflozin23$25,708
Repatha SureclickEvolocumab29$17,322
Metoprolol Succinate150$2,246
Prasugrel Hcl39$1,619
Bumetanide19$1,310
Atorvastatin Calcium132$1,117
ClopidogrelClopidogrel Bisulfate79$1,091
Rosuvastatin Calcium39$663
Valsartan27$592
Carvedilol58$547
Losartan Potassium58$509
Isosorbide Mononitrate ErIsosorbide Mononitrate44$508

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$118$48,55547 claims
Johnson & JohnsonXarelto$124$37,26934 claims
AstraZenecaBrilinta$62$29,65133 claims
Boehringer IngelheimJardiance$273$25,70823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Elmhurst

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →